

**Technology Appraisal Committee D Interests Register**  
**Esketamine for treatment-resistant depression [ID1414]**  
**Publication Date: 14 December 2022**

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor David Meads	TAC Committee Member	Financial	Professor Meads is part of a team that has received research funding from the company to conduct a trial in haematology.	-	07.01.2020	N/A	It was agreed that this declaration would not prevent Professor Meads from participating in discussions on this appraisal.
Professor Hamish McAllister-Williams	Clinical expert	Financial	ACM1 - Hamish McAllister-Williams declared a direct financial interest as his team has received fees for consultancy from Janssen and given talks at Janssen Ad Board for esketamine. Hamish McAllister-Williams also declared a direct non-financial interest as he is recruiting participants to two commercial studies funded by COMPASS pathways and LivaNova.	31.07.2019	07.01.2020 05.08.2020 11.02.2021	N/A	It was agreed that this declaration would not prevent McAllister-Williams from providing expert advice to the committee.

			<p>ACM2 - Hamish McAllister declared financial &amp; non-financial interests as he is recruiting participants to two commercial studies funded by COMPASS pathways and LivaNova, also over the last 3 years he has received fees for consultancy or giving talks at educational meetings from a number of pharmaceutical and neuromodulatory companies including Lundbeck, Sunovian, LivaNova, Magstim, Syntropharma, Pfizer, P1vital and Janssen.</p> <p>ACM3 - Professor Hamish McAllister-Williams declared financial and non-financial interests as he is currently recruiting participants to two commercial studies funded by COMPASS pathways and LivaNova and over the last 3 years he has received fees for consultancy or giving talks at educational meetings from a number of pharmaceutical and</p>				
--	--	--	--	--	--	--	--

			neuromodulatory companies including: Lundbeck, Sunovian, LivaNova, Magstim, Syntropharma, Pfizer, P1vital and Janssen.				
Dr Matt Bradley	TAC Committee Member	Financial	Dr Bradley's employer GSK is identified as a comparator company.	15.07.2020	05.08.2020	N/A	It was agreed that this declaration would not prevent Dr Bradley from participating in discussions on this appraisal.
Mr Giles Monnikendam	TAC Committee Member	Non-financial personal	Mr Monnickendam's employer Vitaccess is developing an observational study for Teva which is a possible comparator company in an unrelated indication [migraine]	14.07.2020	05.08.2020	N/A	It was agreed that this declaration would not prevent Mr Monnickendam from participating in discussions on this appraisal.

David Meads – ACM1 - declared an indirect financial interest as University of Leeds has received research funding from Janssen. This study and therefore potential conflict is on-going. Not declared at ACM2 and Not present at ACM3. ACM 4 - University of Leeds has received funding from Janssen for research in an unrelated area. it was agreed his declaration would not prevent him from participating in discussions on this appraisal

Dr Matthew Bradley – ACM2 - declared a financial interest as his employer GSK is identified as a comparator company. Not declared at ACM1 - ACM3 I am an employee of GSK and hold shares in AstraZeneca, both companies are listed as potential competitor manufacturers. **ACM4 I am an employee of GSK and I hold shares in AstraZeneca, both GSK and AZ are identified as potential competitors for Esketamine. As a direct conflict matt will not participate in discussion on this appraisal.**

Giles Monnickendam – ACM2 - declared a non-financial personal interest as his employer [Vitaccess] is developing an observational study for Teva which is a possible comparator company in an unrelated indication [migraine]. Not present at ACM1 and this was not declared at ACM3. – **ACM4 – NOT DECLARED**

Chris Parker – ACM3 - declared a financial interest as he has received honoraria from Janssen for (i) a lecture on prostate radiotherapy in Feb 2020; (ii) an advisory board on apalutamide in March 2020; (iii) a lecture in November 2020 on PSA failure after treatment for prostate cancer. Not present at ACM1 or ACM2. **ACM4 – NOT DECLARED**

**ACM4** - Dr Ivan Koychev declared professional and financial interests as he has a collaboration with JnJ as part of which blood samples are analysed for biomarkers of neurodegeneration free of charge. The Oxford Department of Psychiatry has received funding from JnJ for an observational study in treatment resistant depression. He was not involved in the study. It was agreed his declaration would not prevent Dr Koychev from participating in discussions on this appraisal.

**Experts:**

**ACM4** - Professor Hamish McAllister-Williams declared financial and non-financial interests as he is currently recruiting participants to two commercial studies funded by COMPASS pathways and LivaNova and over the last 3 years he has received fees for consultancy or giving talks at educational meetings from a number of pharmaceutical and neuromodulatory companies including: Lundbeck, Sunovion, LivaNova, Magstim, Syntropharma, Pfizer, P1vital and Janssen, Takeda and Go North Medical

**ACM4** - Sinead Hayes attended an advisory board on 16 August 2019 to give her experience of MDD and esketamine and a training session on 5 November 2019. She made a video recording of her experience to be used internally at Janssen on 6 January 2020 and a Zoom interview on her experience for Janssen training purposes on 26 May 2020, on all these occasions her expenses were paid by Janssen. It was agreed her declarations would not prevent Sinead from providing expert advice to the committee.